Share-based Payment Arrangement, Expense of PTC THERAPEUTICS, INC. from 31 Dec 2011 to 30 Sep 2025

Taxonomy & unit
us-gaap: USD
Description
Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.
Summary
PTC THERAPEUTICS, INC. quarterly and annual Share-based Payment Arrangement, Expense in USD history and change rate from 31 Dec 2011 to 30 Sep 2025.
  • PTC THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the quarter ending 30 Sep 2025 was $19,426,000, a 1.7% decline year-over-year.
  • PTC THERAPEUTICS, INC. Share-based Payment Arrangement, Expense for the twelve months ending 30 Sep 2025 was $73,268,000, a 0.83% decline year-over-year.
  • PTC THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2024 was $74,615,000, a 27% decline from 2023.
  • PTC THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2023 was $101,636,000, a 7.9% decline from 2022.
  • PTC THERAPEUTICS, INC. annual Share-based Payment Arrangement, Expense for 2022 was $110,333,000, a 6.6% increase from 2021.
Source SEC data
View on sec.gov
Share-based Payment Arrangement, Expense, Trailing 12 Months (USD)
Share-based Payment Arrangement, Expense, Quarterly (USD)
Share-based Payment Arrangement, Expense, YoY Quarterly Change (%)
Share-based Payment Arrangement, Expense, Annual (USD)
Share-based Payment Arrangement, Expense, YoY Annual Change (%)

PTC THERAPEUTICS, INC. Quarterly Share-based Payment Arrangement, Expense (USD)

Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
Q3 2025 $73,268,000 $19,426,000 -$329,000 -1.7% 01 Jul 2025 30 Sep 2025 10-Q 04 Nov 2025 2025 Q3
Q2 2025 $73,597,000 $18,543,000 -$700,000 -3.6% 01 Apr 2025 30 Jun 2025 10-Q 07 Aug 2025 2025 Q2
Q1 2025 $74,297,000 $18,060,000 -$318,000 -1.7% 01 Jan 2025 31 Mar 2025 10-Q 06 May 2025 2025 Q1
Q4 2024 $74,615,000 $17,239,000 +$731,000 +4.4% 01 Oct 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
Q3 2024 $73,884,000 $19,755,000 -$7,187,000 -27% 01 Jul 2024 30 Sep 2024 10-Q 04 Nov 2025 2025 Q3
Q2 2024 $81,071,000 $19,243,000 -$10,128,000 -34% 01 Apr 2024 30 Jun 2024 10-Q 07 Aug 2025 2025 Q2
Q1 2024 $91,199,000 $18,378,000 -$10,437,000 -36% 01 Jan 2024 31 Mar 2024 10-Q 06 May 2025 2025 Q1
Q4 2023 $101,636,000 $16,508,000 -$10,836,000 -40% 01 Oct 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
Q3 2023 $112,472,000 $26,942,000 -$1,728,000 -6% 01 Jul 2023 30 Sep 2023 10-Q 07 Nov 2024 2024 Q3
Q2 2023 $114,200,000 $29,371,000 +$1,641,000 +5.9% 01 Apr 2023 30 Jun 2023 10-Q 08 Aug 2024 2024 Q2
Q1 2023 $112,559,000 $28,815,000 +$2,226,000 +8.4% 01 Jan 2023 31 Mar 2023 10-Q 25 Apr 2024 2024 Q1
Q4 2022 $110,333,000 $27,344,000 +$1,108,000 +4.2% 01 Oct 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
Q3 2022 $109,225,000 $28,670,000 +$2,799,000 +11% 01 Jul 2022 30 Sep 2022 10-Q 26 Oct 2023 2023 Q3
Q2 2022 $106,426,000 $27,730,000 +$2,031,000 +7.9% 01 Apr 2022 30 Jun 2022 10-Q 03 Aug 2023 2023 Q2
Q1 2022 $104,395,000 $26,589,000 +$882,000 +3.4% 01 Jan 2022 31 Mar 2022 10-Q 27 Apr 2023 2023 Q1
Q4 2021 $103,513,000 $26,236,000 +$4,820,000 +23% 01 Oct 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
Q3 2021 $98,693,000 $25,871,000 +$9,092,000 +54% 01 Jul 2021 30 Sep 2021 10-Q 27 Oct 2022 2022 Q3
Q2 2021 $89,601,000 $25,699,000 +$8,789,000 +52% 01 Apr 2021 30 Jun 2021 10-Q 04 Aug 2022 2022 Q2
Q1 2021 $80,812,000 $25,707,000 +$10,487,000 +69% 01 Jan 2021 31 Mar 2021 10-Q 03 May 2022 2022 Q1
Q4 2020 $70,325,000 $21,416,000 +$9,949,000 +87% 01 Oct 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
Q3 2020 $60,376,000 $16,779,000 +$6,295,000 +60% 01 Jul 2020 30 Sep 2020 10-Q 28 Oct 2021 2021 Q3
Q2 2020 $54,081,000 $16,910,000 +$5,990,000 +55% 01 Apr 2020 30 Jun 2020 10-Q 29 Jul 2021 2021 Q2
Q1 2020 $48,091,000 $15,220,000 +$5,957,000 +64% 01 Jan 2020 31 Mar 2020 10-Q 04 May 2021 2021 Q1
Q4 2019 $42,134,000 $11,467,000 +$2,989,000 +35% 01 Oct 2019 31 Dec 2019 10-K 22 Feb 2022 2021 FY
Q3 2019 $39,145,000 $10,484,000 +$1,542,000 +17% 01 Jul 2019 30 Sep 2019 10-Q 29 Oct 2020 2020 Q3
Q2 2019 $37,603,000 $10,920,000 +$2,836,000 +35% 01 Apr 2019 30 Jun 2019 10-Q 05 Aug 2020 2020 Q2
Q1 2019 $34,767,000 $9,263,000 +$1,515,000 +20% 01 Jan 2019 31 Mar 2019 10-Q 30 Apr 2020 2020 Q1
Q4 2018 $33,252,000 $8,478,000 +$2,001,000 +31% 01 Oct 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
Q3 2018 $31,251,000 $8,942,000 +$1,774,000 +25% 01 Jul 2018 30 Sep 2018 10-Q 30 Oct 2019 2019 Q3
Q2 2018 $29,477,000 $8,084,000 +$199,000 +2.5% 01 Apr 2018 30 Jun 2018 10-Q 06 Aug 2019 2019 Q2
Q1 2018 $29,278,000 $7,748,000 -$1,281,000 -14% 01 Jan 2018 31 Mar 2018 10-Q 02 May 2019 2019 Q1
Q4 2017 $30,559,000 $6,477,000 -$1,922,000 -23% 01 Oct 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
Q3 2017 $32,481,000 $7,168,000 -$1,791,000 -20% 01 Jul 2017 30 Sep 2017 10-Q 05 Nov 2018 2018 Q3
Q2 2017 $34,272,000 $7,885,000 -$851,000 -9.7% 01 Apr 2017 30 Jun 2017 10-Q 07 Aug 2018 2018 Q2
Q1 2017 $35,123,000 $9,029,000 +$114,000 +1.3% 01 Jan 2017 31 Mar 2017 10-Q 09 May 2018 2018 Q1
Q4 2016 $35,009,000 $8,399,000 +$550,000 +7% 01 Oct 2016 31 Dec 2016 10-K 01 Mar 2019 2018 FY
Q3 2016 $34,459,000 $8,959,000 +$905,000 +11% 01 Jul 2016 30 Sep 2016 10-Q 02 Nov 2017 2017 Q3
Q2 2016 $33,554,000 $8,736,000 +$408,000 +4.9% 01 Apr 2016 30 Jun 2016 10-Q 09 Aug 2017 2017 Q2
Q1 2016 $33,146,000 $8,915,000 -$833,000 -8.5% 01 Jan 2016 31 Mar 2016 10-Q 08 May 2017 2017 Q1
Q4 2015 $33,979,000 $7,849,000 +$1,143,000 +17% 01 Oct 2015 31 Dec 2015 10-K 06 Mar 2018 2017 FY
Q3 2015 $32,836,000 $8,054,000 +$3,433,000 +74% 01 Jul 2015 30 Sep 2015 10-Q 03 Nov 2016 2016 Q3
Q2 2015 $29,403,000 $8,328,000 +$4,050,000 +95% 01 Apr 2015 30 Jun 2015 10-Q 04 Aug 2016 2016 Q2
Q1 2015 $25,353,000 $9,748,000 +$6,043,000 +163% 01 Jan 2015 31 Mar 2015 10-Q 05 May 2016 2016 Q1
Q4 2014 $19,310,000 $6,706,000 +$3,421,000 +104% 01 Oct 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
Q3 2014 $15,889,000 $4,621,000 +$1,981,000 +75% 01 Jul 2014 30 Sep 2014 10-Q 09 Nov 2015 2015 Q3
Q2 2014 $13,908,000 $4,278,000 +$2,397,000 +127% 01 Apr 2014 30 Jun 2014 10-Q 31 Jul 2015 2015 Q2
Q1 2014 $11,511,000 $3,705,000 +$3,084,000 +497% 01 Jan 2014 31 Mar 2014 10-Q 05 May 2015 2015 Q1
Q4 2013 $8,427,000 $3,285,000 01 Oct 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
Q3 2013 $2,640,000 +$2,119,600 +407% 01 Jul 2013 30 Sep 2013 10-Q 06 Nov 2014 2014 Q3
Q2 2013 $1,881,000 01 Apr 2013 30 Jun 2013 10-Q 07 Aug 2014 2014 Q2
Q1 2013 $621,000 01 Jan 2013 31 Mar 2013 10-Q 06 May 2014 2014 Q1
Q3 2012 $520,400 01 Jul 2012 30 Sep 2012 10-Q 14 Nov 2013 2013 Q3

PTC THERAPEUTICS, INC. Annual Share-based Payment Arrangement, Expense (USD)

Period Value YoY Chg Change % Start Date End Date Report Filed Fiscal Year Fiscal Period
2024 $74,615,000 -$27,021,000 -27% 01 Jan 2024 31 Dec 2024 10-K 27 Feb 2025 2024 FY
2023 $101,636,000 -$8,697,000 -7.9% 01 Jan 2023 31 Dec 2023 10-K 27 Feb 2025 2024 FY
2022 $110,333,000 +$6,820,000 +6.6% 01 Jan 2022 31 Dec 2022 10-K 27 Feb 2025 2024 FY
2021 $103,513,000 +$33,188,000 +47% 01 Jan 2021 31 Dec 2021 10-K 29 Feb 2024 2023 FY
2020 $70,325,000 +$28,191,000 +67% 01 Jan 2020 31 Dec 2020 10-K 21 Feb 2023 2022 FY
2019 $42,134,000 +$8,882,000 +27% 01 Jan 2019 31 Dec 2019 10-K 22 Feb 2022 2021 FY
2018 $33,252,000 +$2,693,000 +8.8% 01 Jan 2018 31 Dec 2018 10-K 25 Feb 2021 2020 FY
2017 $30,559,000 -$4,450,000 -13% 01 Jan 2017 31 Dec 2017 10-K 02 Mar 2020 2019 FY
2016 $35,009,000 +$1,030,000 +3% 01 Jan 2016 31 Dec 2016 10-K 01 Mar 2019 2018 FY
2015 $33,979,000 +$14,669,000 +76% 01 Jan 2015 31 Dec 2015 10-K 06 Mar 2018 2017 FY
2014 $19,310,000 +$10,883,000 +129% 01 Jan 2014 31 Dec 2014 10-K 16 Mar 2017 2016 FY
2013 $8,427,000 +$6,138,000 +268% 01 Jan 2013 31 Dec 2013 10-K 29 Feb 2016 2015 FY
2012 $2,289,000 -$527,637 -19% 01 Jan 2012 31 Dec 2012 10-K 02 Mar 2015 2014 FY
2011 $2,816,637 01 Jan 2011 31 Dec 2011 10-K 06 Mar 2014 2013 FY
* An asterisk sign (*) next to the value indicates that the value is likely invalid.